Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A chromosome-level genome assembly of Neotoxoptera formosana (Takahashi, 1921) (Hemiptera: Aphididae).

G3 (Bethesda, Md.)·2022
Same author

Genetic encoding of an esophageal motor circuit.

Cell reports·2022
Same author

Stress Monitoring of Concrete via Uniaxial Piezoelectric Sensor.

Sensors (Basel, Switzerland)·2022
Same author

Resolving mutational signatures in cancer development.

Cancer cell·2022
Same author

Catalytic mechanisms underlying fungal fatty acid desaturases activities.

Critical reviews in biotechnology·2022
Same author

Recent developments in horizontal gene transfer with the adaptive innovation of fermented foods.

Critical reviews in food science and nutrition·2022

相关实验视频

Updated: May 20, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.5K

多途径研究减少抗氧化的抗药性

Tong Ye1, Chen Wu2, Jintong Na3

  • 1State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Guangxi Medical University, Nanning 530021, China.

Current issues in molecular biology
|March 26, 2025
PubMed
概括

这项研究探讨了在癌症治疗中克服oxaliplatin耐药性的方法. 一种新的CDC7抑制剂,XL413,在提高化疗有效性和减少副作用方面显示出有前途.

关键词:
抗癌机制 抗癌机制 抗癌机制癌症治疗疗法 癌症治疗组合疗法治疗组合治疗.药物耐药性 耐药性 药物耐药性氧化烯酸的氧化烯酸.

更多相关视频

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

相关实验视频

Last Updated: May 20, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.5K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

科学领域:

  • 在瘤学瘤学.
  • 药理学 药理学是指药理学的学科.
  • 癌症生物学 癌症生物学

背景情况:

  • 基于的化疗,包括酸,由于毒性和耐药性而面临限制.
  • 奥克萨利普拉丁是一种至关重要的一线抗瘤药物,需要优化管理以平衡疗效和副作用.

研究的目的:

  • 审查癌症治疗的当前发展,重点关注氧沙的机制,耐药性和改善策略.
  • 调查新型CDC7抑制剂XL413在克服氧沙抗药性和改善治疗结果方面的潜力.

主要方法:

  • 在PubMed和X-MOL数据库的文献搜索中,使用关键字:oxaliplatin,XL413,耐药性,癌症治疗.
  • 应用布尔逻辑来完善相关生物学出版物的搜索策略.
  • 分析了140篇关于氧沙的抗癌作用,耐药性机制以及XL413.的作用的精选出版物.

主要成果:

  • 确定了氧沙的抗癌作用的机制以及临床应用中的挑战.
  • 描述了抗氧化抗性的各种途径及其缓解策略.
  • 突出XL413作为改善基于氧沙的癌症治疗的有希望的药物.

结论:

  • 抗氧化抗性是癌症治疗的一个重大挑战,需要新的治疗方法.
  • XL413提出了一种潜在的策略,以提高氧沙胺化疗的疗效.
  • 对CDC7抑制的进一步研究可能会导致改善癌症治疗方案.